Scarica l'app Stockscreener
20.50
8.36%
-1.87
Precedente Chiudi:
$22.37
Aprire:
$22.37
Volume 24 ore:
2.27M
Relative Volume:
0.97
Capitalizzazione di mercato:
$1.28B
Reddito:
$14.34M
Utile/perdita netta:
$-199.00M
Rapporto P/E:
-5.2296
EPS:
-3.92
Flusso di cassa netto:
$-183.51M
1 W Prestazione:
-20.08%
1M Prestazione:
-4.65%
6M Prestazione:
+40.41%
1 anno Prestazione:
+54.72%
Intervallo 1D:
$20.17
$22.60
Intervallo di 1 settimana:
$20.17
$26.97
Portata 52W:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
20.50 | 1.39B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
Will uniQure N.V. stock split again soonJuly 2025 Price Swings & Accurate Entry/Exit Alerts - mfd.ru
uniqure investor lawsuit deadline set for April 13 following FDA setback By Investing.com - Investing.com India
UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity - Finviz
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - PR Newswire
Class Action Lawsuit Announced for uniQure N.V. - Intellectia AI
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages uniQure N.V. - GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
QURE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against uniQure N.V. - PR Newswire
uniQure (NASDAQ:QURE) Stock Price Down 9.5%What's Next? - MarketBeat
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
uniQure Faces Class Action Lawsuit Over Misleading Statements - Intellectia AI
Will uniQure N.V. benefit from green energy policiesJuly 2025 Drop Watch & Safe Capital Growth Trade Ideas - mfd.ru
UniQure N.V. (QURE) Stock Report: Exploring A 138% Potential Upside In The Biotech Arena - DirectorsTalk Interviews
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - Morningstar
Class Action Lawsuit Filed Against uniQure N.V. - Intellectia AI
uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
UniQure N.V. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsQURE - marketscreener.com
Why is uniQure N.V. stock going downMarket Trend Report & AI Powered Buy/Sell Recommendations - mfd.ru
Why uniQure N.V. stock attracts global investorsJuly 2025 PreEarnings & Free Reliable Trade Execution Plans - mfd.ru
Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE)Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V. Should Contact ... - Bluefield Daily Telegraph
UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large - GlobeNewswire
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - PR Newswire
uniQure Faces Class Action Lawsuit Reminder for Investors - Intellectia AI
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Securities Class Action Filed Against uniQURE N.V. – Investors Encouraged to Contact Kirby McInerney LLP - FinancialContent
Class Action Announcement for uniQure N.V. (QURE): Kessler - GlobeNewswire
Is uniQure N.V. exposed to political riskQuarterly Risk Review & Low Risk Entry Point Guides - mfd.ru
Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Large Losses to Contact the Firm - pharmiweb.com
Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Can uniQure N.V. ride the EV wave2025 Volatility Report & Reliable Volume Spike Trade Alerts - mfd.ru
UniQure Investor Sues Over Delayed Huntington’s Drug Application - Bloomberg Law News
uniQURE Faces Class Action Lawsuit - Intellectia AI
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit - The AI Journal
UNIQURE ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
uniQure N.V. (QURE) Investors: Kessler Topaz Meltzer & Check, LLP Announces That the Firm Has Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. and Encourages Investors to Contact the Firm - The AI Journal
Weekly Recap: Can uniQure NV ride the EV wavePortfolio Return Report & Reliable Intraday Trade Plans - baoquankhu1.vn
uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright - MarketBeat
Risk Hedge: Is BlackRock Multi Sector Income Trust benefiting from innovation trendsJuly 2025 Summary & Long-Term Growth Plans - baoquankhu1.vn
Diamond Hill Capital Management Inc. Sells 49,320 Shares of uniQure N.V. $QURE - MarketBeat
How Early AMT-191 Gene Therapy Signals Will Impact uniQure (QURE) Investors - simplywall.st
Discipline and Rules-Based Execution in QURE Response - Stock Traders Daily
uniQure reports promising data from Fabry disease gene therapy trial By Investing.com - Investing.com Nigeria
UniQure's AMT-191 Sustains Key Enzyme Activity In Fabry Disease In Phase I/IIa Trial; Stock Up - Nasdaq
Uniqure stock rises after AMT-191 gene therapy shows promising Fabry results - Investing.com Nigeria
Uniqure stock rises after AMT-191 gene therapy shows promising Fabry results By Investing.com - Investing.com South Africa
uniQure reports promising data from Fabry disease gene therapy trial - Investing.com
uniQure (QURE) Shares Promising Data on Gene Therapy for Fabry D - GuruFocus
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gut Robert | Director |
Jan 12 '26 |
Sale |
24.62 |
25,613 |
630,483 |
32,342 |
| Kaye Jack | Director |
Jan 09 '26 |
Option Exercise |
19.39 |
6,390 |
123,902 |
26,829 |
| Kaye Jack | Director |
Jan 09 '26 |
Sale |
27.28 |
6,390 |
174,319 |
20,439 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):